Pharmanutra S.p.A.
Milan Stock Exchange PHN.MI
Pharmanutra S.p.A. EBIT Margin for the year ending December 31, 2023: 23.87%
-
Pharmanutra S.p.A. EBIT Margin for the year ending December 31, 2022 was 28.14%, a 5.48% change year over year.
-
Pharmanutra S.p.A. EBIT Margin for the year ending December 31, 2021 was 26.68%, a 10.14% change year over year.
-
Pharmanutra S.p.A. EBIT Margin for the year ending December 31, 2020 was 24.22%, a 7.81% change year over year.
-
Pharmanutra S.p.A. EBIT Margin for the year ending December 31, 2019 was 22.47%, a -11.06% change year over year.
| Date | EBIT Margin | EPS (Basic) | EPS (Diluted) | Shares (Basic, Weighted) |
|---|
Don’t Miss A Beat
| CEO | Mr. Andrea Lacorte |
| IPO Date | July 18, 2017 |
| Location | Italy |
| Headquarters | Via delle Lenze 216/B |
| Employees | 112 |
| Sector | Healthcare |
| Industries | |
Pharmanutra S.p.A., a pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, rest of Europe, the Middle East, Far East, and internationally. The company also produces and markets pharmaceuticals, medical devices, OTC products, and nutraceuticals for pediatric sector; and produces and distributes raw materials and active ingredients for the food, pharmaceutical, and food supplement industries. Its products primarily include SiderAL, SiderAL Forte, SiderAL Folic, Cardio SiderAL, SiderAL Med, Cetilar Crema, Cetilar Patch, Tape, ApportAL, UltraMag, Gestalys DHA, Novomega, Bonecal, and DiKappa 2. The company distributes and sells its products through sales representatives, wholesalers, pharmacies, and para-pharmacies. Pharmanutra S.p.A. was founded in 2003 and is based in Pisa, Italy.
Past 5 years
USD 10.96
USD 8.09
USD 20.04
USD 71.29
USD 18.69
StockViz Staff
February 7, 2025
Any question? Send us an email